Please login to the form below

Not currently logged in
Email:
Password:

eribulin

This page shows the latest eribulin news and features for those working in and with pharma, biotech and healthcare.

BMS and Eisai to collaborate in deal worth up to $3.1bn

BMS and Eisai to collaborate in deal worth up to $3.1bn

Under the agreement, BMS and Eisai will co-commercialise and co-develop MORAb-202, an ADC which combines Eisai’s anti-folate receptor alpha (FRα) antibody farletuzumab and anticancer agent eribulin.. ... MORAb-202 is designed to enter target

Latest news

  • Keytruda monotherapy fails in triple negative breast cancer Keytruda monotherapy fails in triple negative breast cancer

    By contrast, Merck &Co’s phase 3 Keynote-119 trial evaluated Keytruda as a monotherapy for the second or third-line treatment compared to chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine).

  • AZ and Merck & Co get FDA breast cancer nod for Lynparza AZ and Merck & Co get FDA breast cancer nod for Lynparza

    In the OLYMPIAD trial, Lynparza achieved a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared to standard chemotherapy (with capecitabine, vinorelbine or eribulin).

  • NICE set to reject wider use of Eisai’s Halaven NICE set to reject wider use of Eisai’s Halaven

    Issues draft guidance recommending against second-line use in breast cancer. Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to ... According to the appraisal committee “it’s not clear

  • AZ's Lynparza shows PARP inhibitor potential in breast cancer AZ's Lynparza shows PARP inhibitor potential in breast cancer

    Lynparza (olaparib) significantly improved progression-free survival (PFS) in women with HER2-negative metastatic breast cancer with a germline BRCA mutation, when compared with standard therapy with capecitabine, vinorelbine or eribulin

  • AZ moves closer to Lynparza filing in breast cancer AZ moves closer to Lynparza filing in breast cancer

    Compared to standard chemotherapy with capecitabine, vinorelbine or eribulin, Lynparza achieved a "statistically-significant and clinically-meaningful" improvement in progression-free survival (PFS) in the OLYMPIAD trial, said the company, although

More from news
Approximately 4 fully matching, plus 29 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...